文献速递头颈部肿瘤放疗放疗物理与技术

头颈癌自适应数字剂量绘画与非自适应放疗的疾病控制及晚期毒性:一项随机对照2期试验

Disease Control and Late Toxicity in Adaptive Dose Painting by Numbers Versus Nonadaptive Radiation Therapy for Head and Neck Cancer: A Randomized Controlled Phase 2 Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-02-21

这项2中心随机对照2期试验将95例非转移性头颈癌患者按1:1分配至自适应18F-FDG-PET体素强度数字剂量绘画(A-DPBN)或非自适应标准调强放疗(S-IMRT)。A-DPBN组1年和2年局部控制率分别为91%和88%,优于S--IMRT组的78%和75%(HR 3.13,95%CI 1.13-8.71,P=.021);区域控制、总生存及≥3级晚期毒性两组相当。

要点

  • A-DPBN较S-IMRT显著改善1年和2年局部控制(91%/88% vs 78%/75%,HR 3.13,P=.021)。
  • 两组区域控制、总生存及≥3级晚期毒性无显著差异(36% vs 20%,P=.1)。
  • 持续吸烟者≥3级晚期黏膜溃疡更多(29% vs 3%,P=.005),与治疗臂无关。

核心结论

  • A-DPBN较S-IMRT显著改善头颈癌1年和2年局部控制。
  • 作者认为该结果支持在多中心3期试验中进一步探索。
  • 作者指出,由于对持续吸烟者剂量提升相关晚期黏膜溃疡的担忧,招募足够样本量将具有挑战性。

研究设计与样本

  • 2中心随机对照2期试验,按1:1分配患者接受A-DPBN或S-IMRT(±化疗)。
  • 纳入标准:非转移性口腔、口咽/下咽或喉头颈癌需放(化)疗;T1-4N0-3(除外T1-2N0声门癌);KPS≥70;≥18岁;签署知情同意。
  • 共95例患者随机分组(A-DPBN组47例,S-IMRT组48例),中位随访31个月(IQR 14-48个月)。
  • 主要终点为1年局部控制率和区域控制率。

主要发现

  • A-DPBN组1年和2年局部控制率分别为91%和88%,S-IMRT组分别为78%和75%(HR 3.13,95%CI 1.13-8.71,P=.021)。
  • 两组区域控制和总生存相当。
  • 两组总体≥3级晚期毒性分别为36%和20%(P=.1)。
  • 活跃吸烟者≥3级晚期黏膜溃疡发生率29% vs 3%(P=.005),饮酒者33% vs 13%(P=.02),与治疗臂无关。
  • A-DPBN组中,诊断时吸烟者发生≥3级黏膜溃疡显著更多(46% vs 12%,P=.005),≥4级也更多(29% vs 8%,P=.048)。

关键数值与推荐

  • A-DPBN剂量处方在研究过程中根据绝对剂量-体积限值(≤1.75 cm3可接受>84 Gy且归一化等效生物剂量>96 Gy)分两步进行同期自适应调整,作为安全措施,此前4/7例A-DPBN患者发生≥G3黏膜溃疡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出,由于对持续吸烟者剂量提升相关晚期黏膜溃疡的担忧,招募足够样本量进行3期试验将具有挑战性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Local recurrence remains the main cause of death in stage III-IV nonmetastatic head and neck cancer (HNC), with relapse-prone regions within high 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET)-signal gross tumor volume. We investigated if dose escalation within this subvolume combined with a 3-phase treatment adaptation could increase local (LC) and regional (RC) control at equal or minimized radiation-induced toxicity, by comparing adaptive 18F-FDG-PET voxel intensity-based dose painting by numbers (A-DPBN) with nonadaptive standard intensity modulated radiation therapy (S-IMRT). METHODS AND MATERIALS: This 2-center randomized controlled phase 2 trial assigned (1:1) patients to receive A-DPBN or S-IMRT (+/-chemotherapy). Eligibility: nonmetastatic HNC of oral cavity, oro-/hypopharynx, or larynx, needing radio(chemo)therapy; T1-4N0-3 (exception: T1-2N0 glottic); KPS ≥ 70; ≥18 years; and informed consent. PRIMARY OUTCOMES: 1-year LC and RC. The dose prescription for A-DPBN was intercurrently adapted in 2 steps to an absolute dose-volume limit (≤1.75 cm3 can receive >84 Gy and normalized isoeffective dose >96 Gy) as a safety measure during the study course after 4/7 A-DPBN patients developed ≥G3 mucosal ulcers. RESULTS: Ninety-five patients were randomized (A-DPBN, 47; S-IMRT, 48). Median follow-up was 31 months (IQR, 14-48 months); 29 patients died (17 of cancer progression). A-DPBN resulted in superior LC compared with S-IMRT, with 1- and 2-year LC of 91% and 88% versus 78% and 75%, respectively (hazard ratio, 3.13; 95% CI, 1.13-8.71; P = .021). RC and overall survival were comparable between arms, as was overall grade (G) ≥3 late toxicity (36% vs 20%; P = .1). More ≥G3 late mucosal ulcers were observed in active smokers (29% vs 3%; P = .005) and alcohol users (33% vs 13%; P = .02), independent of treatment arm. Similarly, in the A-DPBN arm, significantly more patients who smoked at diagnosis developed ≥G3 (46% vs 12%; P = .005) and ≥G4 (29% vs 8%; P = .048) mucosal ulcers. One arterial blowout occurred after a G5 mucosal toxicity. CONCLUSIONS: A-DPBN resulted in superior 1- and 2-year LC for HNC compared with S-IMRT. This supports further exploration in multicenter phase 3 trials. It will, however, be challenging to recruit a substantial patient sample for such trials, as concerns have arisen regarding the association of late mucosal ulcers when escalating the dose in continuing smokers.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. De Bruycker A, De Neve W, Daisne JF, et al. Disease Control and Late Toxicity in Adaptive Dose Painting by Numbers Versus Nonadaptive Radiation Therapy for Head and Neck Cancer: A Randomized Controlled Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2024. PMID: 38387811. doi:10.1016/j.ijrobp.2024.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。